ClinicalTrials.gg
CompletedNCT02949973AURIONUpdated Mar 19, 2021Results posted

Aurinia Early Urinary Protein Reduction Predicts Response

A Phase 2 interventional study of voclosporin in Lupus Nephritis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 2 sites in Malaysia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Lupus Nephritis with a site in Malaysia — 1 open to participants now, 3 under way, 3 of them phase 3. Lupus Nephritis · Malaysia.

Enrollment
13th of 14
10 · median 104
Started
2015
the only one that year
Phase 2
8 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
2 of 14
Aurinia Pharmaceuticals Inc.

Among the 14 studies in Lupus Nephritis with a site in Malaysia, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 8 in phase 2, and was the 6th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

1 of the 14 studies in Lupus Nephritis with a site in Malaysia is open now. Recruiting first, the newest first:

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Nephritis with a site in Malaysia, or all of them as a file.
02

Study summary

An exploratory study assessing the ability of biomarkers measured at 8 weeks to predict clinical response over 24 and 48 weeks in subjects taking voclosporin 23.7 mg twice daily (BID) in combination with standard of care in patients with active lupus nephritis

Read the detailed description

Voclosporin is a novel calcineurin inhibitor (CNI) intended for use in the prevention of organ graft rejection and for the treatment of autoimmune diseases. The aim of the current development program is to investigate whether voclosporin added to the standard of care treatment in active Lupus Nephritis (LN) is able to reduce disease activity, as measured by a reduction in proteinuria. The background therapy will be mycophenolate mofetil (MMF) 2 g daily, initial treatment with IV methylprednisolone followed by a reducing course of oral corticosteroids. Patients with active, flaring LN will be eligible to enter the study. They are required to have a diagnosis of LN according to established diagnostic criteria (American College of Rheumatology) and clinical and biopsy features suggestive of active nephritis. Efficacy will be assessed by the ability of the drug combination to reduce the level of proteinuria while demonstrating an acceptable safety profile.

03

Conditions studied

  • Lupus Nephritis

Browse trials for

Keywords

  • lupus nephritis
  • calcineurin inhibitors
  • voclosporin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology criteria (1997; see Appendix 6).
  • Kidney within 24 months prior to screening with a histologic diagnosis of lupus nephritis International Society of Nephrology/Renal Pathology Society Classes III, IV-S or IV-G, (A) or (A/C); or Class V, alone or in combination with Class III or IV.
  • Laboratory evidence of active nephritis at screening, defined as: Class III, IV-S or Class IV-G (proteinuria ≥1000 mg/24 hours when assessed by 24 hour urine collection, defined by a urine protein/creatinine ratio (UPCR) of ≥1.0 mg/mg assessed in a first morning void urine specimen). Class V, alone or in combination with Class III or IV, (proteinuria ≥1,500 mg/24 hours when assessed by 24 hour urine collection, defined by a UPCR of ≥1.5 mg/mg assessed in a first morning void urine specimen).

Key Exclusion Criteria:

  • Estimated (eGFR) as calculated by the Chronic Kidney Disease Epidemiology Collaboration equation of ≤45 mL/min/1.73 m2 at screening
  • Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  • A previous kidney transplant or planned transplant within study treatment period.
  • within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision. Subjects with cervical dysplasia that is cervical intraepithelial neoplasia 1, but have been treated with conization or loop electrosurgical excision procedure, and have had a normal repeat Papanicolaou smear test (PAP) are allowed.
  • Lymphoproliferative disease or previous total lymphoid irradiation.
  • Severe viral infection (such as Cytomegalovirus (CMV), virus (HBV), virus (HCV)) within 3 months of screening; or known infection.
  • Active tuberculosis (TB), or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
  • Other known active medical conditions, such as:
  • Severe cardiovascular disease including congestive heart failure, history of cardiac dysrhythmia or congenital long syndrome. QT interval duration corrected for heart rate using method of Fridericia (QTcF) exceeding 480 msec in the presence of a normal QRS interval (\<110 msec) at time of screening will result in exclusion.
  • Liver dysfunction (, alanine aminotransferase, or greater than 2.5 times the ) at screening and confirmed before enrollment.
  • or asthma requiring oral .
  • Bone marrow insufficiency unrelated to active systemic lupus erythematosus (SLE) (according to Investigator judgment) with white blood cell count \<2,500/mm3; \<1.3 × 103/μL; thrombocytopenia ( count \<50,000/mm3).
  • Active bleeding disorders.
  • Current infection requiring IV antibiotics.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Voclosporin

    Voclosporin, oral, 23.7 mg twice daily (BID)

    Drug: voclosporin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR)

    Time frame: 24 weeks

  2. Number of Participants With Reduction or Normalization of Anti ds DNA

    Time frame: 24 weeks

  3. Number of Participants With Reduction or Normalization of C3

    Time frame: 24 weeks

  4. Number of Participants With Reduction or Normalization of C4

    Time frame: 24 weeks

Secondary outcomes

  1. Number of Participants With Complete Remission at Week 24

    * Confirmed Protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥ 60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of ≥20%

    Time frame: week 24

  2. Number of Participants With Complete Remission at Week 48

    * Confirmed Protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥ 60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of ≥20% Safety Population - 2 subjects failed to provide sufficient data to ascertain week 48 response

    Time frame: week 48

07

Results

Posted Mar 19, 2021

Participant flow

Participant flow — Overall Study
MilestoneVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Started10
Completed9
Not completed1
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR)
Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR)
ParticipantsVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR)7
Statistical analysis
  • Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care · Percentage: 70
PrimaryNumber of Participants With Reduction or Normalization of Anti ds DNA
Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction or Normalization of Anti ds DNA
ParticipantsVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Number of Participants With Reduction or Normalization of Anti ds DNA4
Statistical analysis
  • Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care · Percentage: 40
PrimaryNumber of Participants With Reduction or Normalization of C3
Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction or Normalization of C3
ParticipantsVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Number of Participants With Reduction or Normalization of C32
Statistical analysis
  • Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care · Percentage: 20
PrimaryNumber of Participants With Reduction or Normalization of C4
Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants With Reduction or Normalization of C4
ParticipantsVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Number of Participants With Reduction or Normalization of C42
Statistical analysis
  • Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care · Percentage: 20
SecondaryNumber of Participants With Complete Remission at Week 24

* Confirmed Protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥ 60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of ≥20%

Time frame:
week 24
Reported as:
Count of participants · Participants
Number of Participants With Complete Remission at Week 24
ParticipantsVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Number of Participants With Complete Remission at Week 247
Statistical analysis
  • Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care · Percentage: 70 · 95% CI 34.8 to 93.3
SecondaryNumber of Participants With Complete Remission at Week 48

* Confirmed Protein/creatinine ratio of ≤0.5 mg/mg and * eGFR ≥ 60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of ≥20% Safety Population - 2 subjects failed to provide sufficient data to ascertain week 48 response

Time frame:
week 48
Reported as:
Count of participants · Participants
Number of Participants With Complete Remission at Week 48
ParticipantsVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Number of Participants With Complete Remission at Week 484
Statistical analysis
  • Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care · Percentage: 50 · 95% CI 15.7 to 84.3

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care0/10 (0%)3/10 (30%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Acute TonsilitisInfections and infestations1/10
PneumoniaInfections and infestations1/10
AnaemiaBlood and lymphatic system disorders1/10
Pleural effusionRespiratory, thoracic and mediastinal disorders1/10
PyrexiaGeneral disorders1/10
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders1/10
Most frequent other events
Showing 10 of 52
Most frequent other events
EventVoclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
PyrexiaGeneral disorders5/10
Upper Respiratory Tract InfectionInfections and infestations5/10
DiarrhoeaGastrointestinal disorders4/10
Glomerular Filtration Rate DecreasedInvestigations4/10
HypertensionVascular disorders4/10
CoughRespiratory, thoracic and mediastinal disorders3/10
Vision BlurredEye disorders2/10
DyspepsiaGastrointestinal disorders2/10
Chest PainGeneral disorders2/10
Local SwellingGeneral disorders2/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Mean28.7 ± 5.14
Sex: Female, Male
Sex: Female, Male(Participants)Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Female10
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Malaysia10
Duration of systemic lupus erythematosus, proteinuria and lupus nephritis
Duration of systemic lupus erythematosus, proteinuria and lupus nephritis(years)Voclosporin 23.7 mg Twice Daily (BID) in Combination With Standard of Care
Duration of systemic lupus erythematosus (SLE)7.3 ± 3.23
Duration of proteinuria5.9 ± 3.38
Duration of Lupus Nephritis (LN)5.8 ± 3.49
08

Study locations

2 sites
  • AURION Site
    Kuala Lumpur, 50586, Malaysia
  • AURION Site
    Kuala Lumpur, 56000, Malaysia
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Dec 2016 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Oct 31, 2016
Start
Jun 2015
Primary completionActual
Dec 2016
CompletionActual
Feb 17, 2017
Results first posted
Mar 19, 2021
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02949973
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Oct 31, 2016
Start date
Jun 2015
Primary completion
Dec 2016
Completion
Feb 17, 2017
Results posted
Mar 19, 2021
Last update
Mar 19, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion